Join the Spasticity group to help and get support from people like you.
Spasticity News (Page 2)
FDA Approves Fleqsuvy (baclofen oral suspension) for the Treatment of Spasticity
WOBURN, MA, February 7, 2022 – Azurity Pharmaceuticals, Inc., a private specialty pharmaceutical company, focused on developing innovative products to meet the unique needs of patients with u...
FDA Approves Lyvispah (baclofen) Oral Granules for the Treatment of Spasticity
ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Dec. 7, 2021 /PRNewswire/ – Saol Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved Saol's Lyvispah (baclofen)...
FDA Approves Expanded Botox (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity
NORTH CHICAGO, Ill., July 29, 2021 /PRNewswire/ – Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion of Botox® ...
Ipsen Announces Updated Indication for Dysport (abobotulinumtoxinA) for the Treatment of Spasticity in Children
CAMBRIDGE, Mass.--(BUSINESS WIRE) July 09, 2020 --Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration...
FDA Approves Expanded Botox (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity
NORTH CHICAGO, Ill., July 9, 2020 /PRNewswire/ – Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License...
Ipsen Announces FDA approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
June 16, 2017 – Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen) today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved use of Dysport (abobotulinumtoxinA) for injection...
Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older
BASKING RIDGE, N.J., Aug. 1, 2016 /PRNewswire/ – Ipsen Biopharmaceuticals, Inc., a subsidiary of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug...
Ask a question
To post your own question to this support group, sign in or create an account.